William L. Hickerson

William L. Hickerson

Auto-generated profile, based on publicly available information

William L. Hickerson

CMO for Access ProMedical and SiOx Medical , Memphis, TN

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2023 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
PDF file
Yaron ShohamYaron Shoham
Yaron Shoham
LRLior Rosenberg
Lior Rosenberg
WHWilliam Hickerson
William Hickerson
JGJeremy Goverman
Jeremy Goverman
NINarayan Iyer
Narayan Iyer
ASAdam J Singer
Adam J Singer
Since 1970 surgeons have managed deep burns by surgical debridement and autografting. We tested the hypothesis that enzymatic debridement with NexoBrid would remove the eschar reducing surgery and achieve comparable long-term outcomes as standard of care (SOC). In this Phase 3 trial, we randomly assigned adults with deep burns (covering 3–30% of total body surface area [TBSA]) to NexoBrid, surgical or nonsurgical SOC, or placebo Gel Vehicle (GV) in a 3:3:1 ratio. The primary endpoint was complete eschar removal (ER) at the end of the debridement phase. Secondary outcomes were need for surgery, time to complete ER, and blood loss. Safety endpoints included wound closure and 12 and 24-months cosmesis on the Modified Vancouver Scar Scale. Patients were randomized to NexoBrid (n = 75), SOC (n = 75), and GV (n = 25). Complete ER was higher in the NexoBrid versus the GV group (93% vs 4%; P < .001). Surgical excision was lower in the NexoBrid vs the SOC group (4% vs 72%; P < .001). Median time to ER was 1.0 and 3.8 days for the NexoBrid and SOC respectively (P < .001). ER blood loss was lower in the NexoBrid than the SOC group (14 ± 512 mL vs 814 ± 1020 mL, respectively; P < .0001). MVSS scores at 12 and 24 months were noninferior in the NexoBrid versus SOC groups (3.7 ± 2.1 vs 5.0 ± 3.1 for the 12 months and 3.04 ± 2.2 vs 3.30 ± 2.76 for the 24 months). NexoBrid resulted in early complete ER in >90% of burn patients, reduced surgery and blood loss. NexoBrid was safe and well tolerated without deleterious effects on wound closure and scarring.

1 September 1995 in Journal of Burn Care & Rehabilitation
Verified
Journal Article
Closed access
SFSandra Fletchall
Sandra Fletchall
WHWilliam L. Hickerson
William L. Hickerson
As funding for health care becomes a national concern, and workman's compensation and private health insurance companies attempt to limit their expenditures in the treatment of the client with burns, it may become the responsibility of the burn specialists to create a cost-effective approach to quality burn rehabilitation. Our outpatient rehabilitation program has taken a cost-effective approach that limits the use of inpatient rehabilitation, emphasizes the burn team guiding the client to a quick functional return to home and work, and concentrates costs for therapy rather than room and board. This cost-effective rehabilitation approach emphasizes an intensive 6-hours-per day, 5-days-per-week outpatient program that begins immediately after discharge. In a 2 ½- year follow-up of this cost-effective program, the following were identified. (1) A 40% reduction in costs for third-party payers and (2) clients returning to work an average of 4 months after their injury. In die cost-effective rehabilitation approach, 82% of the health care costs are concentrated for therapy. In the traditional inpatient rehabilitation program, room and board costs comprise 57% of the charges. Because it is the responsibility of the burn specialists to educate the health care payers, a program description to implement the cost-effective approach to burn rehabilitation is provided.

2 June 2025 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
JCJeffrey E Carter
Jeffrey E Carter
JSJeffrey W Shupp
Jeffrey W Shupp
HPHerb A Phelan
Herb A Phelan
WHWilliam Hickerson
William Hickerson
CCClay J Cockerell
Clay J Cockerell
JHJames H Holmes
James H Holmes
Background: With the advent of convolutional neural networks (CNNs), artificial intelligence is now applicable to visual fields. We used multispectral imaging (MSI) sensors capable of detecting wavelengths outside visible spectra to image burn wounds. The output was converted to pixel-level data and analyzed by an array of CNNs to inform the development of a deep learning (DL) algorithm for burn assessment. Methods: Three burn centers prospectively grouped consenting subjects into those with wounds likely to heal nonoperatively by 21 days, or those benefiting from surgery. Both groups underwent MSI sensor imaging at enrollment and once daily until discharge/excision. Nonoperative subjects were evaluated at 21 days, while operative subjects underwent biopsies. A “Truthing Panel” of burn experts created a “ground truth” for each wound that was converted to pixel-level data and used to train ten CNNs (8 unique DL algorithms and 2 ensemble DL algorithms). Results: 1037 MSI images and 161 biopsies were collected from 100 adult and 24 pediatric subjects. The most effective CNN algorithm exhibited an area under the curve of 0.95 (accuracy = 89.29%, sensitivity = 90.51%, and specificity = 87.22%) with the covariate “time-since-injury” found to be significant (P < .0001). Accuracy was lowest, 88.5%, at 1-2 days after injury and highest, 93.5%, at 3-4 days. The CNN’s learning curve predicted an accuracy of 94.04% after enrolling 374 subjects in a future training study. Conclusions: An optimal CNN architecture and the importance of “time-since-injury” as a covariate were identified, informing the design/powering of upcoming algorithm training and validation studies.

19 March 2024 in Journal of Burn Care & Research
Verified
Journal Article
Open access
PDF file
PGPaul Glat
Paul Glat
LQLisa Quirk
Lisa Quirk
SHScott Hultman
Scott Hultman
JKJennifer Kesey
Jennifer Kesey
AJArpana Jain
Arpana Jain
WHWilliam L Hickerson
William L Hickerson
The goal of this study was to inform standards of best practice in the use of cultured epidermal autograft (CEA), manufactured in the United States, for the treatment of patients with severe burns. The study was designed using the modified Delphi technique, a method for structuring group communication among experts to promote the development of consensus-based recommendations. Known areas of variability related to the stages of CEA treatment were identified by literature review prior to the study and were confirmed through qualitative interview with the experts. The areas included Preoperative Planning/Surgical Planning, Immediate Postoperative Care, and Rehabilitation and Long-Term Care. A list of 22 questions was developed based on interviews with the experts, and a 3-round Delphi technique was used to establish consensus (≥80% agreement). Following 3 rounds (quantitative, qualitative, and virtual roundtable meeting) of the Delphi study, important guidance for the use of CEA treatment in severely burned patients gained consensus. Final key recommendations included minimum burn limit for CEA treatment (30%-50% TBSA), ideal biopsy timing (1-2 days), number of grafts (enough to cover; adjust 72 hours before application), use of dermal substrates (recommended) and wide meshed autograft underlay (recommended), optimal CEA drying time per day (open air >6 hours), slings used if CEA placed on extremities (recommended), dressing changes (performed every day, all at once, with all layers removed down to bridal veil), CEA backing removal (10-14 days after placement), heat lamps (can be used to aid the wound in drying, depending on clinical judgment), initial activity restrictions lifted (beginning 10 days after backing removal), compression garments (introduced at approximately 2 months post-CEA surgery), and lasers (CO2 laser can be introduced between 3 and 6 months post-CEA surgery).

10 July 2013 in Journal of Mass Spectrometry
Verified
Journal Article
Open access
PDF file
ZHZhe‐Yi Hu
Zhe‐Yi Hu
BBBradley A. Boucher
Bradley A. Boucher
SLSteven Casey Laizure
Steven Casey Laizure
VHVanessa L. Herring
Vanessa L. Herring
RPRobert B. Parker
Robert B. Parker
WHWilliam L. Hickerson
William L. Hickerson
A hydrophilic interaction chromatography/mass spectrometry (HILIC‐MS)‐based assay for imipenem (IMP) and cilastatin (CIL) was recently reported. This orthogonal electrospray ion source‐based (ORS) assay utilized nonvolatile salt (unremovable) to stabilize IMI in plasma. Unfortunately, this method was not applicable to conventional MS with off‐axis spray (OAS‐MS) because MS sensitivity was rapidly deteriorated by the nonvolatile salt. Therefore, we aimed to find a nonvolatile salt‐ and ion suppression‐free approach to stabilize and measure the analytes in plasma using OAS‐MS. Acetonitrile and methanol were tested to stabilize the analytes in the plasma samples. The recoveries, matrix effects and stabilities of the analytes in the stabilizer‐treated samples were studied. The variations in MS signal intensities were used as the indicator of the assay ruggedness. The results show that a mixture of methanol and acetonitrile (1:1) is best for the storage and measurement of IMP and CIL in human plasma. Utilization of this precipitant not only blocked the hydrolysis of the analytes in plasma but also resulted in an ion suppression‐free, fast (120 s per sample) and sensitive detection. The sensitivity obtained using the less sensitive OAS‐MS (API3000, 4 pg on column) is much greater than that of the published ORS‐MS‐based assay (API4000, 77 pg on column). The ruggedness of the assay was demonstrated by its constant MS signal intensity. In conclusion, an improved HILIC/MS‐based assay for IMP and CIL was established. The approach presented here provides a simple solution to the challenge of analyzing hydrolytically unstable β‐lactam antibiotics in biological samples. Copyright © 2013 John Wiley & Sons, Ltd.

9 September 2023 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
PDF file
DHDavid M Hill
David M Hill
BYBing Yang
Bing Yang
SLSteven Casey Laizure
Steven Casey Laizure
BBBradley Boucher
Bradley Boucher
JSJoseph Swanson
Joseph Swanson
SVSai R Velamuri
Sai R Velamuri
Patients with augmented renal clearance (ARC) are a subset of critically ill patients including burn patients that exhibit increased renal elimination of medications beyond that of similarly injured patients. Currently approved maximum regimens of medications primarily eliminated by the kidney, such as cefepime (>90% unchanged in the urine), may be inadequate (eg, compromising the bactericidal activity of cefepime) in patients with ARC. Due to recent resource limitations, centers have changed infusion practices of commonly prescribed medications to intravenous push (IVP), potentially exacerbating the problem of maintaining bactericidal cefepime concentrations. The hypothesis of the study was patients with ARC are not currently achieving adequate target attainment, when receiving cefepime 2 g every 8 h IVP. Eight blood samples were collected from each patient, and concentrations measured via LC–MS/MS. WinNonlin (version 8.3) was used to estimate the pharmacokinetic parameters of cefepime and simulate plasma concentrations of cefepime in each of the ten subjects. Simulations of cefepime plasma concentrations produced by a 2 g dose given every 8 h and a 1 g dose given every 4 h were performed and the time above a MIC of 4 mg/L, 8 mg/L, and 16 mg/L compared. The 2 g every 8 h regimen remained above the breakpoints for 92%, 85%, and 71% of the dosing interval, respectively. The 1 g every 4 h regimen remained above the same breakpoints at a frequency of 100%, 99%, and 92% of the dosing interval. Giving cefepime 1 g every 4 h is a simple approach to increase the likelihood of maintaining the optimal bactericidal activity of cefepime in patients with ARC.